Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating R
about
Statins for primary prevention of venous thromboembolismStatins for primary prevention of venous thromboembolismRosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspectiveAre cardiovascular benefits in statin lipid effects dependent on baseline lipid levels?Polypill therapy, subclinical atherosclerosis, and cardiovascular events-implications for the use of preventive pharmacotherapy: MESA (Multi-Ethnic Study of Atherosclerosis)Rosuvastatin: a review of the pharmacology and clinical effectiveness in cardiovascular disease.Association between inflammatory markers and liver fat: The Multi-Ethnic Study of AtherosclerosisJUPITER and satellites: Clinical implications of the JUPITER study and its secondary analyses.The change in motivating factors influencing commencement, adherence and retention to a supervised resistance training programme in previously sedentary post-menopausal women: a prospective cohort study.Estimating treatment effects for individual patients based on the results of randomised clinical trials.Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial.Comparison of the Framingham and Reynolds Risk scores for global cardiovascular risk prediction in the multiethnic Women's Health InitiativeRole of disease risk scores in comparative effectiveness research with emerging therapiesC-reactive protein level and the incidence of eligibility for statin therapy: the multi-ethnic study of atherosclerosis.Initiation of statin therapy: are there age limits?Cardiovascular risk biomarkers in CKD: the inflammation link and the road less traveled.The evolution or revolution of statin therapy in primary prevention: where do we go from here?Searching the place of pitavastatin in the current treatment of patients with dyslipidemia.Benefit-risk assessment of rosuvastatin in the treatment of atherosclerosis and related diseases.Management of Cardiovascular Risk in Patients with Chronic Inflammatory Diseases: Current Evidence and Future Perspectives.The Role of Statin Therapy for Primary Prevention: What is the Evidence?Statins and mortality: the untold story.
P2860
Q24187238-FC03E4A5-2F7D-4B20-9A5E-2B13ABC045EBQ24204040-D46BA2DB-9D31-4699-9D95-AFB012428ECDQ24594814-99D7C25A-67FD-4B30-B37F-E5CA64F70B1FQ34151632-378C4E81-5929-4975-9064-349207CF64EBQ34240747-17301573-311E-4C68-A77A-649C6BD3FE79Q34636887-0944A312-EC3B-45CA-B173-1AC60B86EA70Q34976232-7EC5F4ED-CC2D-4301-9135-B087B95F7E17Q35172886-22323E0B-9D4A-482E-A517-E32D14273C42Q35184940-E42A9087-0594-40CC-8385-9645B8942BECQ35252544-82C52385-1149-4D11-8002-D26B447AED28Q35756468-172C9B3C-E167-439A-84B3-B611A1B546D0Q35884178-3A4C9BF4-E546-4D93-9178-48149ED7B0FFQ36266471-247B99D8-466F-4D27-8CCA-E1DF359737DBQ37636023-A4F6A5E8-2125-40A7-9A16-D0D266AB1DEFQ37956537-ABF643AF-DBFF-455A-8FAF-65F9377EF78CQ38042361-EC269DD1-3392-4215-ABFE-B1941DDEC6F9Q38072612-1B235510-02BE-4B44-BD4E-953315FE2D30Q38161516-6E64E6AA-3014-4CAC-B0D5-714226800198Q38208727-2A0A0A10-032C-414F-8D38-0A4A58A982DCQ38972344-F1B641CF-FB87-4DAB-9B56-D54ADDC9C7FCQ51177261-72F13B58-4C11-4A3E-9760-88ABDEE3C988Q53645752-C8441E4F-F6A7-4862-83D6-B7669BD8C8A4
P2860
Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating R
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Rosuvastatin for primary preve ...... ntervention Trial Evaluating R
@en
type
label
Rosuvastatin for primary preve ...... ntervention Trial Evaluating R
@en
prefLabel
Rosuvastatin for primary preve ...... ntervention Trial Evaluating R
@en
P2093
P1476
Rosuvastatin for primary preve ...... ntervention Trial Evaluating R
@en
P2093
Jacques Genest
Jean G Macfadyen
John J P Kastelein
Paul M Ridker
Robert J Glynn
P304
P356
10.1161/CIRCOUTCOMES.110.938118
P577
2010-08-24T00:00:00Z